jRCT2051210045进行中（未招募）不适用
ONO-7475-03: ONO-7475 Phase I Study An open-label, uncontrolled study of ONO-7475 in combination with osimertinib in EGFR gene mutation-positive non-small cell lung cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 75
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients with stage IIIB/IIIC/IV or recurrent NSCLC, which is unsuitable for radical irradiation
- •Patients with confirmed EGFR gene exon 19 deletion or EGFR gene exon 21 mutation(L858R)and who are scheduled to receive osimertinib
- •Patient has an ECOG performance status of 0-1
排除标准
- •Patients with severe complication
- •Patients with multiple primary cancers
结局指标
主要结局
-
Tolerability, safety
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
ONO-7475-03 : ONO-7475 Phase 1 StudyEGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiationJPRN-jRCT2051210045Osawa Masahiro75
进行中（未招募）
1 期
ONO-4578-03:ONO-4578 Phase 1 StudyJPRN-jRCT2051200096Hirashima Yoshinori30
进行中（未招募）
不适用
ONO-7475-04:A Phase1 study of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and ONO-7475 in combination with GnP in patients with pancreatic cancerjRCT2031230429Ono Pharmaceutical Co.,LTD87
进行中（未招募）
1 期
ONO-4578-05:ONO-4578 Phase 1 Studyon-small cell lung cancerJPRN-jRCT2031200346Osawa Masahiro40
招募中
不适用
ONO-4915-01:ONO-4915 Phase I study
A study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ONO-4915 in Japanese healthy adult malesjRCT2071240056Ono Pharmaceutical Co.,LTD160